Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | KMO | O15229 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FYN | P06241 | 1/20 | 0.41 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.41 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17295620 | 1.00 | IDO1 (0.44) | IDO1ESR2ALOX5PTGS2KMO | |
| SCHEMBL17291033 | 0.82 | SMN1; SMN2 (0.42) | KMOMAPT | |
| SCHEMBL23402778 | 0.81 | NPC1 (0.49) | IDO1KMONPC1MAPTRAB9A | |
| SCHEMBL4765637 | 0.81 | MAPT (0.48) | IDO1NPC1GAAMAPTRAB9A | |
| SCHEMBL1716280 | 0.81 | MAPT (0.50) | NPC1MAPTRAB9A | |
| SCHEMBL16664794 | 0.81 | CTSS (0.44) | IDO1ESR2ALOX5GAAMAPT | |
| SCHEMBL16667664 | 0.80 | CYP11B1 (0.50) | NPC1MAPTMAPK1RAB9A | |
| SCHEMBL28067324 | 0.80 | IDO1 (0.44) | IDO1PTGS2NPC1GAAMAPT | |
| SCHEMBL25645955 | 0.80 | ESR2 (0.44) | IDO1ESR2KMONPC1GAA | |
| SCHEMBL25719682 | 0.80 | METAP2 (0.42) | MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3059235-B1 | TETRAZOLINONE DERIVATIVES AND THEIR USE FOR CONTROLLING PESTS | SUMITOMO CHEMICAL CO (JP) | 2020-10-28 | — | — | EP | disclosed |
| EP-3059235-B1 | TETRAZOLINONE DERIVATIVES AND THEIR USE FOR CONTROLLING PESTS | SUMITOMO CHEMICAL CO (JP) | 2020-10-28 | — | — | EP | disclosed |
| EP-3148972-B1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10085450-B2 | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2018-10-02 | — | — | US | disclosed |
| US-9682938-B2 | Pyrazolone derivatives as nitroxyl donors | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| EP-3148972-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | Cardioxyl Pharmaceuticals Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-20160270399-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160270399-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-22 | — | — | US | disclosed |
| US-20160270399-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2016-09-22 | — | — | US | disclosed |
| EP-3059235-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | Sumitomo Chemical Company, Ltd. (JP) | 2016-08-24 | — | — | EP | disclosed |
| EP-3059235-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | Sumitomo Chemical Company, Ltd. (JP) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015183839-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2015-12-03 | — | — | WO | disclosed |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY | 2015-12-03 | — | — | US | disclosed |
| WO-2015056806-A1 | TETRAZOLINONE COMPOUND AND APPLICATION FOR SAME | 住友化学株式会社 | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10085450-B2 | Tetrazolinone compound and use thereof | ROS1, TCOF1, RPS20 | IDO1 2339/4885ESR2 3393/4885ALOX5 3343/4885 |
| US-20150344437-A1 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS | TNNI3, PFKP, NOX5 | IDO1 1124/4885ESR2 2731/4885ALOX5 325/4885 |
| US-20160270399-A1 | TETRAZOLINONE COMPOUND AND USE THEREOF | ROS1, TCOF1, RPS20 | IDO1 2339/4885ESR2 3393/4885ALOX5 3343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.